

| Table 1. Examples of Test Name Errors With Nonsensical Test Names |  |
|---|--|
| Test Performed  | Test Name in Reports Before Correction |
| PAX-5   | PAX-8 5                                |
| Ki-67   | Ki-1-67 or K-67                        |
| Keratin 5   | 35                                     |
| P120  | Pp20                                   |
| Ker 8/18  | Ker 5/18                               |
| CD56  | p56                                    |
| TTF-1   | TTF-                                   |
| GATA-3  | GAT3                                   |

| Table 2. Examples of Test Name Errors Using Different Test Names |  |
|--|--|
| Test Performed   | Test Name in Reports Before Correction |
| Estrogen receptor  | Progesterone receptor                  |
| CD30   | CD38                                   |
| CK5  | CD5                                    |
| CD138  | CD38                                   |
| CD34   | CD117                                  |
| p63  | p16                                    |
| BCL-2  | BCL-6                                  |
| CD56   | Chromogranin                           |

Not all the effective tools are practical if they are burdensome to use, specifically if the users have to remember to use the tools or a nontrivial effort is required to use the tools. The advantage of computational monitoring is that it does not require pathologists to remember to use the tool. The program keeps a constant vigilance in the background and notifies the pathologists in a timely fashion when possible omission is noted.

R is not only strong in statistical computing and graphics, it is also powerful in dealing with texts/natural language. In surgical pathology, R has been reported to be used in statistical analysis,<sup>2</sup> information extraction from the report texts,<sup>1,3</sup> pathology report defect detection,<sup>4</sup> and deep learning using report diagnosis texts.<sup>5</sup>

The specific use example of R program in improving the reporting of ancillary tests demonstrates that computational approach can be an effective way to improve standardization in pathology reporting in general. R is a practical language that pathologists can learn and use to produce immediate positive impact in daily practice.

Jay J. Ye, MD, PhD

Dahl-Chase Pathology Associates, Bangor, Maine

1. Ye JJ. Pathology report data extraction from relational database using R, with extraction from reports on melanoma of skin as an example. *J Pathol Inform.* 2016;7:44.

2. Cuff J, Higgins JP. Statistical analysis of surgical pathology data using the R program. *Adv Anat Pathol.* 2012;19(3):131–139.

3. Boag A. Extraction and analysis of discrete synoptic pathology report data using R. *J Pathol Inform.* 2015;6:62.

4. Ye JJ, Tan MR. Computational algorithms that effectively reduce report defects in surgical pathology. *J Pathol Inform.* 2019;10:20.

5. Ye JJ. Construction and utilization of a neural network model to predict current procedural terminology codes from pathology report texts. *J Pathol Inform.* 2019;10:13.

Accepted for publication March 10, 2020.

The author has no relevant financial interest in the products or companies described in this article.

Supplemental digital content is available for this article at [www.archivesofpathology.org](http://www.archivesofpathology.org) in the August 2020 table of contents.

doi: 10.5858/arpa.2020-0013-LE

## Synoptic Report Response Options Directly Impact Patient Care

*To the Editor.*—It has previously been shown that the use of a checklist such as the one used in synoptic reporting can lead to a more complete surgical pathology report,<sup>1–3</sup> and that different methods of generating a synoptic report can also affect the completeness of that report.<sup>4–6</sup> The presence or absence of clinically significant data elements may impact the clinical management of a patient. Formatting of the synoptic report can also impact pathologists' ability to create a synoptic report and a clinician's ability to interpret that report.<sup>4,5,7–15</sup> To date, the impact of the choices that are presented to the pathologists as responses to any data element on the data in the report or the management of the patient has not been studied. In the Word-based synoptic reports offered by the College of American Pathologists (CAP) and its electronic Cancer Checklist, a discrete set of options is presented with limited use of qualifying terms.<sup>8</sup> However, previous studies suggest that many pathologists prefer to in-

clude qualifying terms (ie, “suspicious for,” “extensive,” etc) and they may use free-text entry to achieve this result when the choice is not offered to them.<sup>8</sup> To assess whether presenting qualified responses in a synoptic report has an impact on the report content or patient care, we compared the response for the data element “lymphovascular invasion” (LVI) in our laboratory from 240 consecutive cases (60 each from endometrium, colon, lung, and breast) using the CAP Word-based synoptic reports system (“no qualified choices,” between January 1 and June 30, 2015) with a Web-based method that did include qualifying terms among the selection choices (between August 1, 2016, and December 31, 2019).<sup>14</sup>

Results are presented in the Table. Free-text options were used less than 2% of the time for both groups. Both “suspicious for LVI” and “extensive LVI” were entered as free-text options (once each) in the reports with no qualified options presented. Although there was no significant difference in the rate of LVI when cases in which LVI was either present or extensive (22% versus 26%;  $P = .23$ ), there were significantly more cases identified as having LVI when cases diagnosed as suspicious for LVI were included and presented as an option (23% versus 34%;  $P = .01$ ). There were also significantly fewer cases diagnosed as indeterminate when qualified responses were offered (17% versus 6%;  $P = .001$ , 2-tailed  $\chi^2$  test).

During this time period, whenever an endometrial carcinoma case was presented at Gynecologic Tumor Board in which the use of adjuvant therapy was not clear, the presence or absence of LVI was always discussed. Patients whose LVI status was reported as indeterminate were considered to have the same risk as patients whose LVI status was reported as not identified. However, patients who were labeled as suspicious for LVI were identified as at higher risk of recurrence than patients without LVI or those who were classified as indeterminate, and patients with extensive LVI were identified as having a higher risk of recurrence than patients who were labeled as LVI without any qualifier. In one case, the clinicians decided that they would treat the patient only if the LVI were extensive, and it was asked that the case be rereviewed to assess this. The findings were similar in the tumor boards for

| Comparison of Qualified and Unqualified Response Options in Synoptic Reports for “Lymphovascular Invasion” |   |            |   |            |
|--|---|------------|---|------------|
| Response Choices   | No Qualified Responses Listed               |            | Qualified Responses Listed                  |            |
|  | Included in List of Data Element Responses? | No. (%)    | Included in List of Data Element Responses? | No. (%)    |
| Not identified   | Yes   | 155 (65)   | Yes   | 146 (61)   |
| Indeterminate  | Yes   | 33 (14)    | Yes   | 15 (6)     |
| Suspicious   | No  | 1 (1)      | Yes   | 18 (8)     |
| Present  | Yes   | 50 (21)    | Yes   | 47 (20)    |
| Present, extensive   | No  | 1 (1)      | Yes   | 14 (6)     |
| <b>Total</b>   |   | <b>240</b> |   | <b>240</b> |

other sites, but these results were not specifically tracked.

There are limitations to this study. We compared consecutive series of cases and did not match them for grade, tumor size, or stage. However, there was no difference in the overall rate of cases with LVI when cases diagnosed as suspicious for LVI were excluded, suggesting that the cases were similar, and that the differences we observed are related to pathologists simply choosing “indeterminate” when “suspicious for LVI” was not offered as a choice. In addition, we compared the performance of the same pathologists at different times, and their performance may have changed over time.

In summary, we have shown that not only does the inclusion of qualified responses for LVI in synoptic reports result in increased reporting of LVI and decreased reporting of indeterminate cases, but reporting of LVI directly impacts patient care in a subset of patients with synoptic reports. Clinicians routinely include their own assessment of the signifi-

cance of these qualifying terms in their recommendations for patient management. Further study to ensure that the response options that are presented in the CAP synoptic report protocols are evidence based seems warranted.

Andrew A. Renshaw, MD<sup>1</sup>; Troy Gatliff, MD<sup>2</sup>; Edwin W. Gould, MD<sup>1</sup>

Departments of <sup>1</sup> Pathology and Surgery, Baptist Health of South Florida, Miami; <sup>2</sup> Miami Cancer Institute, Miami, Florida

1. Srigley JR, McGowan T, Maclean A, et al. Standardized synoptic cancer pathology reporting: a population-based approach. *J Surg Oncol*. 2009; 99(8):517–524.

2. Karim RZ, van den Berg KS, Colman MH, McCarthy SW, Thompson JF, Scolyer RA. The advantage of using a synoptic pathology report format for cutaneous melanoma. *Histopathology*. 2008;52(2):130–138.

3. Gill AJ, Johns AL, Eckstein R, et al. Synoptic reporting improves histopathological assessment of pancreatic resection specimens. *Pathology*. 2009; 41(2):161–167.

4. Renshaw AA, Gould EW. The cost of synoptic reporting. *Arch Pathol Lab Med*. 2017;141(1):15–16.

5. Renshaw AA, Mena-Allauca M, Gould EW, Sirintrapun SJ. Synoptic reporting: evidence-based review and future directions. *JCO Clin Cancer Inform*. December 2018;2:1–9. doi:10.1200/CCI.17.00088

6. Renshaw AA, Gould EW. Root cause analysis of amendments in tumor summaries. *Arch Pathol Lab Med*. 2020;144(4):414–415.

7. Renshaw AA, Gould EW. Comparison of accuracy and speed of information identification by nonpathologists in synoptic reports with different formats. *Arch Pathol Lab Med*. 2017;141(3):418–422.

8. Renshaw AA, Gould EW. Improving discrete data capture in synoptic reports with optional free text modifiers. *JCO Clin Cancer Inform*. 2018;2:1–6. doi:10.1200/CCI.17.00127

9. Renshaw AA, Gould EW. Use of a Web-based checklist to improve compliance with Medicare Access and CHIP Reauthorization Act of 2015 reporting. *Arch Pathol Lab Med*. 2018;142(11):1312.

10. Renshaw AA, Gould EW. Updates and customizations in synoptic reporting. *Arch Pathol Lab Med*. 2018;142(12):1452–1453.

11. Renshaw AA, Mena-Allauca M, Gould EW. Tabular versus synoptic reporting of prostate core needle biopsies. *JCO Clinical Cancer Informatics*. 2017;1:1–7.

12. Renshaw AA, Mena-Allauca M, Gould EW. Reporting Gleason grade/score in synoptic reports of radical prostatectomies. *J Pathol Inform*. 2016;7:54.

13. Renshaw AA, Mena-Allauca M, Gould EW. Reporting margin status in synoptic reports. *JCO Clin Cancer Inform*. 2017;1:1–8. doi:10.1200/CCI.16.00056

14. Renshaw MA, Renshaw SA, Mena-Allauca M, et al. Performance of a web-based method for generating synoptic reports. *J Pathol Inform*. 2017;8:13. doi:10.4103/jpi.jpi\_91\_16

15. Renshaw SA, Mena-Allauca M, Touriz M, Renshaw A, Gould EW. The impact of template format on the completeness of surgical pathology reports. *Arch Pathol Lab Med*. 2014;138(1):121–124.

Accepted for publication April 10, 2020.

The authors have no relevant financial interest in the products or companies described in this article.

doi: 10.5858/arpa.2020-0181-LE